Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors

Contributed by: Business Wire

Logo

Tags

Research

Women

Clinical Trials

Biotechnology

Health

Consumer

Pharmaceutical

Science

Oncology

Debio 0123

More Like This

Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

Debiopharm & WhiteLab Genomics Announce a Strategic Partnership to Advance Drug Target and Design in Oncology